Patents by Inventor Jerald C. Sadoff

Jerald C. Sadoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210246170
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: January 30, 2021
    Publication date: August 12, 2021
    Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
  • Publication number: 20200197509
    Abstract: Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×1010 to about 2×1011 viral particles (vp), are described.
    Type: Application
    Filed: September 13, 2018
    Publication date: June 25, 2020
    Inventors: Myra Noorely WIDJOJOATMODJO, Olivier GODEAUX, Kristi Lynn WILLIAMS, Benoit Christophe Stephan CALLENDRET, Jerald C. SADOFF
  • Publication number: 20200061181
    Abstract: Compositions, vaccines and methods using adenovirus vectors for inducing protective immunity against a respiratory syncytial virus (RSV) infection are described.
    Type: Application
    Filed: May 15, 2018
    Publication date: February 27, 2020
    Applicant: Janssen Vaccines & Prevention B.V.
    Inventors: Olivier GODEAUX, Jerald C. SADOFF, Macaya Julie DOUOGUIH
  • Patent number: 8728492
    Abstract: Malaria vaccines based on polyepitope constructs that elicit cell-mediated immunity against a broad spectrum of malaria parasites and which cover the majority of HLA alleles are provided. Epitopes in the polyepitope constructs are from regions of the Plasmodium falciparum circumsporozoite protein (CSP) known to contain CD4 and CD8 T cell epitopes, and include both epitopes from highly variable and highly conserved regions of CSP.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: May 20, 2014
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Avigdor Shafferman, Anat Zvi, John Fulkerson, Jerald C. Sadoff
  • Patent number: 8658136
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: February 25, 2014
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.
  • Patent number: 8609402
    Abstract: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: December 17, 2013
    Assignees: Aeras Global TB Vaccine Foundation, Crucell Holland B.V
    Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Rado{hacek over (s)}evic
  • Publication number: 20130224242
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Application
    Filed: April 8, 2013
    Publication date: August 29, 2013
    Applicant: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, JR.
  • Patent number: 8414884
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 9, 2013
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.
  • Patent number: 8361482
    Abstract: A vaccine against Mycobacteria tuberculosis (Mtb) is provided. The vaccine comprises a recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which one or more Mtb antigens and one or more Mtb resuscitation or reactivation antigens are overexpressed, and in which at least a portion of the DosR regulon is up-regulated. The vaccine is protective against active Mtb infection both pre- and post-exposure to Mtb, and thus prevents disease symptoms due to the recurrence of a latent Mtb infection.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: January 29, 2013
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Avigdor Shafferman, Anat Zvi, Naomi Ariel, John Fulkerson, Roaggai Sun, Rosemary Chang, Jerald C. Sadoff
  • Patent number: 8202723
    Abstract: Described are vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Also described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: June 19, 2012
    Assignees: Crucell Holland B.V., Aeras Global TB Vaccine Foundation
    Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Rado{hacek over (s)}evic
  • Publication number: 20110281347
    Abstract: Described are vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Also described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.
    Type: Application
    Filed: May 31, 2011
    Publication date: November 17, 2011
    Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Radosevic
  • Patent number: 8053568
    Abstract: Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to form rdsRNs de novo.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: November 8, 2011
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: David Hone, John Fulkerson, Jerald C. Sadoff, David Onyabe, Michele Stone
  • Patent number: 8043857
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomalytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell; and antigens of interest, such as tuberculosis antigens. The invention also provides vaccine preparations containing such Mycobacterium strains.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: October 25, 2011
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Publication number: 20110256166
    Abstract: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.
    Type: Application
    Filed: May 31, 2011
    Publication date: October 20, 2011
    Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Radosevic
  • Publication number: 20110206714
    Abstract: Malaria vaccines based on polyepitope constructs that elicit cell-mediated immunity against a broad spectrum of malaria parasites and which cover the majority of HLA alleles are provided. Epitopes in the polyepitope constructs are from regions of the Plasmodium falciparum circumsporozoite protein (CSP) known to contain CD4 and CD8 T cell epitopes, and include both epitopes from highly variable and highly conserved regions of CSP.
    Type: Application
    Filed: January 12, 2009
    Publication date: August 25, 2011
    Inventors: Avigdor Shafferman, Anat Zvi, John Fulkerson, Jerald C. Sadoff
  • Publication number: 20110117124
    Abstract: Viral-based vectors are genetically engineered to express inhibitors of the anti-viral immune system (e.g. inhibitors of the type I interferon response) in order to enhance transgene expression. The transgenes may encode antigens or other therapeutic agents.
    Type: Application
    Filed: August 29, 2008
    Publication date: May 19, 2011
    Inventors: Jerald C. Sadoff, John Fulkerson, Mohamad Fakruddin-Jamiluddin, Michele R. Stone, Ravi Anatha
  • Publication number: 20110117133
    Abstract: A vaccine against Mycobacteria tuberculosis (Mtb) is provided. The vaccine comprises a recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which one or more Mtb antigens and one or more Mtb resuscitation or reactivation antigens are overexpressed, and in which at least a portion of the DosR regulon is up-regulated. The vaccine is protective against active Mtb infection both pre- and post-exposure to Mtb, and thus prevents disease symptoms due to the recurrence of a latent Mtb infection.
    Type: Application
    Filed: November 13, 2009
    Publication date: May 19, 2011
    Inventors: Avigdor Shafferman, Anat Zvi, Naomi Ariel, John Fulkerson, Roaggai Sun, Rosemary Chang, Jerald C. Sadoff
  • Patent number: 7935354
    Abstract: A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant mycobacterium that overexpresses the transcription factor DosR, at a level sufficient to induce production of the dosR regulon genes or proteins. A host to whom the vaccine is administered mounts an immune response to the dosR regulon proteins and is thus protected from the establishment, persistence or reactivation of latent tuberculosis.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: May 3, 2011
    Assignees: Aeras Global TB Vaccine Foundation, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mario Alberto Flores-Valdez, Gary K. Schoolnik, Michel Klein, Jerald C. Sadoff, David Hone
  • Publication number: 20110086066
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Application
    Filed: December 10, 2010
    Publication date: April 14, 2011
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, JR.
  • Patent number: 7883696
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: February 8, 2011
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.